Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABAA Receptor

Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models

(2019) Karine Leclercq et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Puzzling Out Synaptic Vesicle 2 Family Members Functions

(2017) Odile Bartholome et al.   Frontiers in Molecular Neuroscience

Immunochemical analysis of the expression of SV2C in mouse, macaque and human brain

(2017) Amy R. Dunn et al.   BRAIN RESEARCH

Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond

(2016) Wolfgang Löscher et al.   CNS DRUGS

The Role of Benzodiazepines in the Treatment of Epilepsy

(2016) Juan G. Ochoa et al.   Current Treatment Options in Neurology

Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein

(2016) Martyn D. Wood et al.   EPILEPSIA

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment

(2016) Henrik Klitgaard et al.   EPILEPSIA

Understanding transport by the major facilitator superfamily (MFS): structures pave the way

(2016) Esben M. Quistgaard et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Activation-induced regulation of GABAA receptors: Is there a link with the molecular basis of benzodiazepine tolerance?

(2016) María Clara Gravielle   PHARMACOLOGICAL RESEARCH

A Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release

(2016) Kentaro Tokudome et al.   Frontiers in Pharmacology

Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission

(2016) Kentaro Tokudome et al.   Scientific Reports

Brivaracetam augments short-term depression and slows vesicle recycling

(2015) Xiaofeng Yang et al.   EPILEPSIA

Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays

(2013) V Daniels et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Pharmacology of Imepitoin: The First Partial Benzodiazepine Receptor Agonist Developed for the Treatment of Epilepsy

(2013) Chris Rundfeldt et al.   CNS DRUGS

Synaptic vesicle protein 2A: basic facts and role in synaptic function

(2013) Julieta Griselda Mendoza-Torreblanca et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Expression pattern of synaptic vesicle protein 2 (SV2) isoforms in patients with temporal lobe epilepsy and hippocampal sclerosis

(2013) J. Crèvecœur et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Levetiracetam has an activity-dependent effect on inhibitory transmission

(2012) Anna L. Meehan et al.   EPILEPSIA

Structure, Function, and Modulation of GABAAReceptors

(2012) Erwin Sigel et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Altered balance between excitatory and inhibitory inputs onto CA1 pyramidal neurons from SV2A-deficient but not SV2B-deficient mice

(2012) Kumar Venkatesan et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties

(2011) Michel Gillard et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam

(2011) Anna L. Meehan et al.   JOURNAL OF NEUROPHYSIOLOGY

Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes

(2011) Uwe Rudolph et al.   NATURE REVIEWS DRUG DISCOVERY

Distribution of SV2C mRNA and protein expression in the mouse brain with a particular emphasis on the basal ganglia system

(2010) D. Dardou et al.   BRAIN RESEARCH

The complexity of the GABAA receptor shapes unique pharmacological profiles

(2009) Charlotte D’Hulst et al.   DRUG DISCOVERY TODAY

Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam

(2009) Rafal M. Kaminski et al.   EPILEPSIA

SV2 Renders Primed Synaptic Vesicles Competent for Ca2+-Induced Exocytosis

(2009) W.-P. Chang et al.   JOURNAL OF NEUROSCIENCE

Benzodiazepines in epilepsy: pharmacology and pharmacokinetics

(2008) J. Riss et al.   ACTA NEUROLOGICA SCANDINAVICA

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A

(2008) A Matagne et al.   BRITISH JOURNAL OF PHARMACOLOGY

Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam

(2008) Rafal M. Kaminski et al.   EPILEPSIA

SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

(2007) Rafal M. Kaminski et al.   NEUROPHARMACOLOGY